Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Exchange rate changed
AGREEMENT
NOW, THEREFORE, in consideration of the mutual agreements, covenants, promises and representations set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and accepted, and intending to be legally bound hereby, the parties agree as follows:
1. Definitions. Each capitalized term used but not defined in this Amendment shall have the meaning assigned to such term in the Merger Agreement.
2. Amendment to Section 2.01(c) of the Merger Agreement. The phrase “will be converted into the right to receive 0.02731 validly issued, fully paid and non-assessable share of Parent Common Stock (the “Merger Consideration”)” in Section 2.01(c) of the Merger Agreement is hereby deleted and replaced in its entirety by the following:
“will be converted into the right to receive 0.05 validly issued, fully paid and non-assessable share of Parent Common Stock (the “Merger Consideration”)”
3. Amendment to Section 3.03(c) of the Merger Agreement. The phrase “will be exchanged for shares of Parent Common Stock at an average exchange ratio of 0.9709” in Section 3.03(c) of the Merger Agreement is hereby deleted and replaced in its entirety by the following”
Does the following SEC report indicate that Forian owns 46% of HLIX before the Merger?
[url][/url]https://www.sec.gov/Archives/edgar/data/1611277/000121390020035308/ea129390-13da1forian_helix.htm
Wouldnt this mean that HLIX non-insiders would only own ~10-13% of Forian after merger?
rodman and renshaw
Just a reminder Rodman and Renshaw have soligenix listed as a presenting company.
http://www.rodmanandrenshaw.com/conferences?id=162&link=presenters
I doubt there will be any big bomb shells as soligenix would probably made it more known.
the schedual is tomorrow at 10:50AM
http://www.meetmax.com/sched/event_9601/~public/h/conference_presentations.html?event_id=9601
RICIN
I was just reading it Holllllly Cow
WASHINGTON | Fri Aug 12, 2011 11:20pm EDT
(Reuters) - The Obama administration is concerned that a dangerous regional arm of al Qaeda is trying to produce the deadly poison ricin to use in attacks against the United States, the New York Times reported Friday.
Citing unnamed intelligence officials and classified intelligence reports, the newspaper said al Qaeda's affiliate in Yemen has been trying to acquire large quantities of castor beans, used to produce ricin.
It said the apparent intent was to pack the poison around small explosives that could be exploded to disperse the ricin, a white powdery substance so deadly that a speck can kill if inhaled or taken into the bloodstream.
The Times said the apparent intent was to detonate the explosives in enclosed spaces like a shopping mall or airport.
President Barack Obama and top security aides were briefed about the threat last year, the report said, and have received updates since then but added that senior American officials said there was no indication an attack was imminent.
The Times noted that there were limits on ricin's utility as a weapon because it loses its potency in dry, sunny conditions -- like those in Yemen -- and is not easily absorbed through the skin like some other nerve agents.
Senior administration officials said ricin was among the threats being tracked by a secret government task force created after printer cartridges packed with powerful explosives were found in cargo bound for Chicago in October 2010, according to the Times report.
It said the task force was working with Saudi officials and with the remnants of Yemen's intelligence agencies to counter the threat. It said regional al Qaeda affiliates, especially al Qaeda in the Arabian Peninsula, were seen as a menace to the United States and U.S. interests abroad.
The virtual collapse of Yemen's government has enabled al Qaeda to widen its control in the country and strengthen its operational ties with al Shabab, the Islamic militancy in Somalia, the Times said.
Not bad day for SNGX I actualy sold a couple ounces of gold i had saved and bought another 12K of sngx today
Thats exactly what happend in january 07 right after they published their pivital phase 3 results. If you look at the chart then and now, it looks the same to me. I expect the same jump as back then after they publish the confirmatory phase 3 results
imho the thing that makes this price so undervalued is the lack of institutional investors. Most institutional investors via policy do not touch pennys. I feel it is still slightly off radar but not for to long (i hope). Daytraders dont help, some have been waiting for a long time and so there are proffit takers and those who just saw a way to brake even, add to that the fact that there are no fda approvals and everything is in phase 2 or under except Orbec. And of course confirmatory phase 3 of Orbec has no guarantee of success.
Now with all that said, confirmatory phase 3 of Orbec has a high probability of success due to what we know about the previous phase 3 and due to the co party (FDA SNGX) design of the confirmatory phase 3.
but imho there are many reasons to buy and they are stated by posters here who have done their dd.
Completely agree on your speculation. I do hope something is up behind closed doors. Been here since '07 and picked up most of my shares when she dropped under a dime (just wish i bought more). not selling a share till i see at least $1.
Its great to see alot of new names join this board. My only little complaint is the delay in orbec phase 3 but hell i guess i can wait a few more months. lord oh lord phase 3 results will be so critical. I realy expect the results to be beyond doubt and if that is true I think pps will rise as if FDA already aproved it.
GLTA
Ive notice everytime this thing looks to make a move thousands of shares show up and hold it back down. I have no idea how to read this.. manipulation? looking to unload? happy to sell? I dont know.
after reading about celgene, I wonder if they are setting the stage for a buyout? just a thought no real credence.
Celgene Corporation and its subsidiaries (collectively "we", "our" or "us") is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. Our primary commercial stage products include REVLIMID®, VIDAZA®, THALOMID® (inclusive of Thalidomide Celgene® and Thalidomide Pharmion®), ABRAXANE®, which was obtained in the October 2010 acquisition of Abraxis BioScience, Inc., or Abraxis, and ISTODAX®, which was obtained in the January 2010 acquisition of Gloucester Pharmaceuticals, Inc., or Gloucester.
We continue to invest substantially in research and development, and the drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs® compounds, which are a class of compounds proprietary to us that have certain immunomodulatory and other biologically important properties in addition to our leading oral anti-inflammatory agents and cellular therapies. We believe that continued acceptance of our primary commercial stage products, depth of our product pipeline, regulatory approvals of both new products and expanded use of existing products, provide the catalysts for future growth
I guess im wrong about no news:
http://www.soligenix.com/news.aspx?titleId=372
Sorry and glta
Nice way to start the week, I knew people were watching this one. The lack of news kind of bothers me, seems this may just all be speculation but I welcome it. Can you imagine what positive news would do to this!! Over 10X trading volume over $1M in trades I like it. With any luck some of these are insider buys that will help once that hits the sec. Come on SNGX dont let me down like back in '07.
I think the share holder meeting is today @9:30 any verification or news on that?
They are on point and always seem to have time to talk to investors. They are very canded and upfront. I remember calling them around their last cc and asking about the posability of the reverse split (still autherized) and they said they had no plans in the near future unless it was truely benificial to do.
I am holding this baby till I see at least $1.50 or it goes out of buisiness.
GTLA
Thank you Han1,
Very helpful,
Thank you again for your time.
Ouch, you dont think there is any room to flip before then?
Hi there,
Quick Q, is the market cap really around 17Mill or does anybody have a better approximation?
Also im thinking about getting back in, (got out a while ago at a small loss)so what kind of entry points are people looking at?
thanks
Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer
http://www.prnewswire.com/news-releases/soligenix-appoints-kevin-horgan-md-as-chief-medical-officer-115000449.html
Soligenix Nabs Exclusive License to Vaccine Thermostabilization Technology
http://www.genengnews.com/gen-news-highlights/soligenix-nabs-exclusive-license-to-vaccine-thermostabilization-technology/81244601/
Soligenix Receives $245,810 in Non-Dilutive Financing from New Jersey's Technology Business Tax Certificate Transfer Program
http://www.prnewswire.com/news-releases/soligenix-receives-245810-in-non-dilutive-financing-from-new-jerseys-technology-business-tax-certificate-transfer-program-114544684.html
Soligenix Receives FDA Orphan Drug Designation for RiVax™ for the Prevention of Ricin Intoxication
http://www.prnewswire.com/news-releases/soligenix-receives-fda-orphan-drug-designation-for-rivax-for-the-prevention-of-ricin-intoxication-114267249.html
Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
http://www.prnewswire.com/news-releases/soligenix-announces-positive-preliminary-results-of-sgx202-in-radiation-injury-114099564.html
GLTA
I emailed their IR email asking if they submitted an maa like they said they were going to do my end of last year. I got no reply, I sent the email about a week ago.
according to their last letter to stockholders they should be filling for MAA this quarter but I havent heard anything. except those job offers. I would love to know if thay are still on target. "stay on target" lol
I think one thing is important to note and that is MIAMI has a hella lot of money walking around. And as money starts to notice the title trucks rolling around and get a bit interested, they might just be seeing an investment op. But then again id like to see more volume with this gain so who knows.
? positively or negatively?
Soligenix Receives Award Totaling $244,479 for orBec® Program From Qualifying Therapeutic Discovery Project
http://www.genengnews.com/industry-updates/soligenix-receives-award-totaling-244-479-for-orbec-program-from-qualifying-therapeutic-discov/99207798/
PRINCETON, N.J., Nov. 3, 2010 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, announced today that the Company has been awarded a cash grant totaling $244,479 under the U.S. Internal Revenue Service's Qualifying Therapeutic Discovery Project (QTDP) program. The awards are intended for projects designed to treat or prevent diseases by conducting studies for the purpose of securing approval from the U.S. Food and Drug Administration.
Soligenix Announces Completion of Enrollment and Preliminary Safety Results of a Phase 1B Clinical Trial for RiVax
http://www.smartbrief.com/news/fdli/industryPR-detail.jsp?id=459DA20C-B25A-4FF1-9954-21E2AB94EF26
new 10-Q
http://sec.gov/cgi-bin/browse-edgar?company=calypte&match=&CIK=&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
mostly what I expected but did see this little paragraph, may have a small spark of life left in this company. longshot
"During the second quarter of 2010, we continued our focus on restarting our modest research and development operations and finalizing the restructuring of our debt. We are continuing to make progress with our small research and development staff. We continue to make fresh batches of AwareTM HIV-1/2 OMT rapid tests and our AwareTM BED Incidence kits. Despite our limited resources, our research and development staff has continued our preliminary investigation into the Aware II platform, including a preliminary community trial in Portland, Oregon. The AwareTM II line provides a cassette-housed strip in a unique two-step platform that we have licensed from Ani Biotech Oy (the “Ani Platform”). This license and the associated technology provides us the platform and the required technology to commercially sell into the developed world markets."
ricin found in home and FBI investigates
http://abclocal.go.com/wtvg/story?section=news/local&id=7747989&status=ok
I just do a google search on companies I havent heard from in a while and sort it by date. anything that doesnt look like a regergitation from months or years back i take a look at. sometimes i get lucky.
take a look at the company history section in the 10Q. bgem started as a mineral rights or mining company. I guess they gave up on their original venture and got into the distribution game.
Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
http://www.bioportfolio.com/news/article/219626/Soligenix-Announces-Preliminary-Results-Of-Its-Phase-2-Clinical-Trial-Of-Orbec.html
PRINCETON, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, today reported preliminary results from its Phase 2 "proof-of-concept" exploratory clinical trial of orBec® for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period. The preliminary results indicate that orBec® appears safe and well tolerated in this patient population, but did not achieve statistical significance in the primary endpoint, which was the proportion of subjects who developed acute GVHD with severity sufficient to require systemic immunosuppressive treatment on or before day 90 after transplantation. However, an encouraging result was that use of orBec® resulted in fewer cases of more severe acute GVHD grades IIb-IV (21% vs. 33% of patients receiving placebo), although this difference was not statistically significant. This result has the potential to be clinically relevant because GVHD grades IIb-IV are associated with more severe disease involving the skin and liver as well as being associated with poorer outcomes, including mortality rates that approach 100% in the grade IV patient population. Further analysis of the complete dataset continues and is aimed at identifying other potential effects seen with orBec® in preventing acute GVHD.
The Phase 2 prevention study was a randomized, double-blind, placebo-controlled trial that enrolled 140 patients who had been randomized to either orBec® or placebo at a 2:1 ratio. Prior to HCT, patients began study drug at the start of their conditioning regimen and continued through day 75 following HCT. The study was conducted primarily at the Fred Hutchinson Cancer Research Center in Seattle, WA and was supported, in large part, by a National Institutes of Health (NIH) grant. The impetus for this NIH-funded prevention study came from two double-blind, randomized, placebo-controlled trials showing that orBec® was effective and safe as a treatment for acute gastrointestinal (GI) GVHD.
Paul J. Martin, MD, Principal Investigator for the Phase 2 study and a Member, Fred Hutchinson Cancer Research Center stated,
"Trials with orBec® have shown a consistent and positive clinical response in the treatment of acute GI GVHD. We therefore designed a trial to determine whether orBec® could be used to prevent GVHD. Preliminary analysis indicates that administration of orBec® starting before transplantation did not provide a statistically significant clinical advantage in preventing acute GVHD in this study, possibly because of confounding factors associated with the chemotherapy or radiation. Preventive administration of orBec® to reduce the incidence or severity of GVHD warrants further investigation, for example, by starting orBec® dosing after transplantation, closer to the initial inflammatory insult of acute GVHD. We are continuing to analyze the data in order to gain a better understanding of potential preventive treatment effects in this patient population and to determine the best approach for subsequent study."
Dr. Martin continued,
"In my mind, the results from this prevention study have no clinical implication regarding the likelihood of success in the ongoing Phase 3 study of orBec® for the treatment of acute GI GVHD."
"This Phase 2 clinical trial was truly proof-of-concept and the first of its kind. It was an aggressive approach to determining if a topically-active steroid therapy, like orBec®, could have an impact on preventing the development of GVHD very early in the disease process,"
added Brian L. Hamilton, MD, PhD, Chief Medical Officer of Soligenix.
"The trend towards less severe acute GVHD in the patients treated with orBec® is encouraging. We are continuing to analyze the Phase 2 data for other clinically meaningful signals."
Dr. Hamilton continued,
"We obviously remain confident in the ultimate success of our confirmatory Phase 3 study of orBec® in the treatment of acute GI GVHD. This Phase 3 trial is anchored by more than 15 years of clinical research in the treatment setting, including positive results from two prior randomized, double-blind, placebo-controlled studies. The current Phase 3 study is designed to replicate the endpoint of treatment failure rate at Study Day 80, which was successfully measured as a secondary endpoint (p-value 0.005) in the Company's previous Phase 3 study. Accordingly, there is no correlation between the prospects for success in these distinctly different therapeutic indications and patient populations. We continue to make good progress towards completing the confirmatory Phase 3 trial in treatment of acute GI GVHD in the second half of next year."
I hope Soligenix can benefit from this
http://www.forbes.com/2010/10/21/bioterror-vaccines-manufacturing-technology-breakthroughs-biodefense.html?partner=yahootix
very nice article published online today.
http://www.ijmm.org/article.asp?issn=0255-0857;year=2010;volume=28;issue=4;spage=295;epage=298;aulast=Ingole
~ Abstract
Purpose: Integrated counselling and testing centres (ICTC) provide counselling and blood testing facilities for HIV diagnosis. Oral fluid tests provide an alternative for people whodo not want blood to be drawn. Also, it avoids the risk of occupational exposure. The goal of this study was to evaluate the utility of Calypte AWARE HIV-1/2 OMT antibody test as a screening test in an Indian setting. Materials and Methods: A cross-sectional study was carried out after ethics committee approval in 250 adult ICTC clients. Blood was collected and tested from these clients for HIV diagnosis as per routine policy and the results were considered as the gold standard. Also, after another written informed consent, oral fluid was collected from the clients and tested for the presence of HIV antibodies. Twenty five clients who had and 25 clients who had not completed their secondary school education (Group A and Group B, respectively) were also asked to perform and interpret the test on their own and their findings and experiences were noted. Result: The sensitivity, specificity, PPV and NPV of the oral fluid antibody test were 100%, 98.51%, 94.11% and 100%, respectively. Seventy six percent of clients preferred oral fluid testing. Group B found it difficult to perform the test as compared to Group A and this difference was statistically significant (P = 0.05). Conclusion: Oral fluid testing can be used as a screening test for HIV diagnosis; however, confirmation of reactive results by blood-based tests is a must.
Acusphere, Inc. is seeking candidates for a Senior Engineer, Manufacturing who will lead certain aspects of the technical transfer of an aseptic manufacturing process to a contract manufacturing organization for eventual commercial production; develop, optimize and trouble-shoot pharmaceutical processes; and develop appropriate equipment and process qualification and validation protocols, standard operating procedures (SOPs) and manufacturing batch records.
all posted today
http://www.biospace.com/job_view.aspx?JOB_ID=281490
http://www.biospace.com/job_view.aspx?JOB_ID=281491
http://www.biospace.com/job_view.aspx?JOB_ID=281489
we're number 1 we're number 1 yeahhhh lol
check out this little article good luck all.
https://news.fidelity.com/news/news.jhtml?articleid=201010190630STREETCMREALTIME_10891860&IMG=N&cat=default&ccsource=rss-default
The share holder meeting is today, i think it started at 10AM. Any word as to what the outcomes are?